Shining on Major News : Amgen Inc. (NASDAQ:AMGN), Digi International Inc. (NASDAQ:DGII), Meritage Homes Corporation (NYSE:MTH), ERBA Diagnostics, Inc. (NYSEMKT:ERB), WESCO International (NYSE:WCC)

On SEP 5, Amgen Inc. (NASDAQ:AMGN) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2014, at the Grand Hyatt New York in New York City, beginning at 9:10 a.m. ET. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference.  Amgen Inc. (NASDAQ:AMGN) belongs to Healthcare sector. Its net profit margin is 25.70% and weekly performance is -0.58%. On last trading day company shares ended up $137.88. Amgen Inc. (NASDAQ:AMGN) distance from 50-day simple moving average (SMA50) is 9.59%.

On AUG 27, Digi International Inc (NASDAQ:DGII) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a research noteissued to investors on Tuesday. The firm currently has a $8.60 price objective on the stock. Zacks‘s price objective points to a potential upside of 2.02% from the stock’s previous close. Digi International Inc. (NASDAQ:DGII) shares increased 0.36% in last trading session and ended the day at $8.36. DGII Gross Margin is 48.20% and its return on assets is 1.10%. Digi International Inc. (NASDAQ:DGII) quarterly performance is -9.82%.

On AUG 26, Meritage Homes Corporation (NYSE:MTH) has received a consensus recommendation of “Hold” from the ten ratings firms that are currently covering the stock,Analyst Ratings Net reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and five have issued a buy recommendation on the company. On 05 September, Meritage Homes Corporation (NYSE:MTH) shares fell -0.18% and was closed at $39.83. MTH EPS growth in last 5 year was 18.40%. Meritage Homes Corporation (NYSE:MTH) year to date (YTD) performance is -17.00%.

ERBA Diagnostics, Inc. (NYSEMKT:ERB), a fully integrated in vitro diagnostics company, on AUG 12 announced its results of operations for the second quarter of 2014. Net income increased to $450,436 for the second quarter of 2014, or earnings of $0.01 per diluted share, compared to net income of $87,333 for the second quarter of 2013, or earnings of $0.00 per diluted share. Total revenues increased to $7,540,657 for the second quarter of 2014, a 9.5% increase, compared to $6,889,259 for the second quarter of 2013. ERBA Diagnostics, Inc. (NYSEMKT:ERB) ended the last trading day at $3.23. Company weekly volatility is calculated as 6.98%and price to cash ratio as 52.49. ERBA Diagnostics, Inc. (NYSEMKT:ERB) showed a weekly performance of -10.53%.

On JULY 25, WESCO International Inc. (NYSE:WCC)’s second quarter 2014 earnings of $1.29 cents per share missed the Zacks Consensus Estimate by 4 cents. However, earnings increased 32.5% sequentially and 3.0% on a year-over-year basis. Improved sales volumes in Canada, acquisition pipeline, organic sales growth and better pricing led to the increase in bottom line performance. WESCO International Inc. (NYSE:WCC) shares fell -1.11% in last trading session and ended the day on $83.79. WCC Gross Margin is 20.40% and its return on assets is 5.20%. WESCO International Inc. (NYSE:WCC) quarterly performance is -8.12%.